scholarly journals Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan

2017 ◽  
Vol 108 (7) ◽  
pp. 1414-1420 ◽  
Author(s):  
Toshifumi Tada ◽  
Takashi Kumada ◽  
Hidenori Toyoda ◽  
Kunihiko Tsuji ◽  
Atsushi Hiraoka ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatic Resection ◽  
Multicenter Study ◽  
Intermediate Stage

Hepatic Resection for “BCLC Stage A” Hepatocellular Carcinoma. The Prognostic Role of Alpha-Fetoprotein

2011 ◽  
Vol 19 (2) ◽  
pp. 426-434 ◽  
Author(s):  
Roberto Santambrogio ◽  
Enrico Opocher ◽  
Mara Costa ◽  
Matteo Barabino ◽  
Massimo Zuin ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatic Resection ◽  
Alpha Fetoprotein ◽  
Prognostic Role

scholarly journals Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making

2016 ◽  
Vol 115 (9) ◽  
pp. 1039-1047 ◽  
Author(s):  
Yong-Fa Zhang ◽  
Jie Zhou ◽  
Wei Wei ◽  
Ru-Hai Zou ◽  
Min-Shan Chen ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Decision Making ◽  
Hepatic Resection ◽  
Intermediate Stage

Efficacy trend of hepatic resection for hepatocellular carcinoma with large multinodular tumor or macrovascular invasion.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 427-427 ◽  
Author(s):  
Jian-Hong Zhong ◽  
Le-Qun Li ◽  
Xin-Ping Ye ◽  
Yang Ke ◽  
Lin Wang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Liver Function ◽  
Hepatic Resection ◽  
Tertiary Care ◽  
Disease Free Survival ◽  
Recent Decade ◽  
Free Survival ◽  
Disease Free

427 Background: Official guidelines and retrospective studies have different view on the role of hepatic resection (HR) for patients with large (≥5 cm) multinodular (≥2) hepatocellular carcinoma (HCC) and those involving macrovascular invasion (MVI). We aim to evaluate the efficacy and its variation trend and the safety of HR for these patients in three tertiary care settings. Methods: A consecutive sample of 1,824 patients with Child-Pugh A liver function and large/multinodular HCC or involving MVI and who underwent initial HR were divided into four groups: large/multinodular HCC of the previous (2000-2004, n = 496) and recent five years (2005-2010, n = 765), involving MVI of the previous (n = 242) and recent five years (n = 321). Results: Among our patient sample, the hospital mortality was less than 5% and had a downward trend. Moreover, patients in recent five years have statistically significant longer survival time. Among patients with large/multinodular HCC, patients in recent five years showed a significantly better overall survival than those in previous five years at 1-year (92% vs. 84%), 3-year (69% vs. 61%), and 5-year (45% vs. 40%) (P = 0.004). Moreover, among patients involving MVI, overall survival in recent five years was significantly higher at 1-year (83% vs. 78%), 3-year (50% vs. 41%), and 5-year (25% vs. 17%) (P= 0.033). However, the disease-free survival of recent five years was only slightly higher than that of the previous five years in the two subgroups. Conclusions: HR offers good overall survival for patients with resectable large/multinodular HCC or those involving MVI and with preserved liver function. Outcomes have tended to improve in recent decade.

The efficacy and safety of lenvatinib in patients with intermediate-stage hepatocellular carcinoma: A nationwide multicenter study in Japan.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 548-548
Author(s):  
Kaoru Tsuchiya ◽  
Masayuki Kurosaki ◽  
Azusa Sakamoto ◽  
Hiroyuki Marusawa ◽  
Chikara Ogawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Multicenter Study ◽  
Objective Response ◽  
Progression Free Survival ◽  
Intermediate Stage ◽  
Median Number ◽  
Observation Time ◽  
Efficacy And Safety ◽  
Free Survival ◽  
Modified Recist

548 Background: Lenvatinib (LEN) has been used in patients with unresectable hepatocellular carcinoma (u-HCC) since Mar 2018 in Japan. We conducted a nationwide multicenter study and especially focused on the efficacy and safety in the patients with intermediate-stage u-HCC. Methods: A total of 240 patients received LEN from March 2018 at 15 sites in Japan was enrolled. Tumour assessments in accordance with modified RECIST were done using dynamic CT or MRI within 4-8 weeks and every 6-8 weeks thereafter. Results: In this study, 88 of 240 (36.7%) patients were BCLC stage B. Among them 76 (86.3%) patients received TACE before LEN and the median number of TACE was 2 (1-10). Only 4 patients were TKI experienced and other 84 (95.5%) patients received LEN as a 1st line therapy. The median pretreatment ALBI score was -2.35 and 75 (85.2%) patients were Child-Pugh A. In this cohort, 73 (83.0%) patients were beyond up-to-seven criteria and the median pretreatment AFP was 38.2 (2-12870) ng/mL. The median observation time was 8.5 months and 16 patients died. The median progression free survival was 8.7 months, and the median overall survival (OS) was not reached. Objective response rate (ORR) and disease control rate (DCR) were 48.5% and 80.3%. AFP decrease ( > 20%) after 1 month was observed in 52 (59.0%) patients. Child-Pugh B patients (n = 13) had significantly shorter OS than Child-Pugh A (p = 0.02) and median OS in Child-Pugh B patients was 8.8 months. The patients received > 6 times TACE before LEN had significantly shorter OS than patients received ≤ 6 times TACE (p = 0.02). Additional TACE was performed in 8 patients and The median time of restarting LEN was 19 days. The median ALBI score before additional TACE, Day 1 after TACE and Day 28 after TACE were -2.38, -2.07, and -2.36.There was no severe adverse event associated with additional TACE. The median duration of LEN in patients treated with LEN and additional TACE was 8.5 months. Conclusions: The ORR and DCR of LEN in Child-Pugh A patients with intermediate-stage HCC were 46.6% and 79.3%. The therapeutic strategies for intermediate-stage HCC should be discussed based on the liver function, tumor states, and treatment course about TACE.

scholarly journals Hepatic Resection Provides Survival Benefit for Selected Intermediate-Stage (BCLC-B) Hepatocellular Carcinoma Patients

2019 ◽  
Vol 51 (1) ◽  
pp. 65-72 ◽  
Author(s):  
Zhang Zhaohui ◽  
Shen Shunli ◽  
Chen Bin ◽  
Li Shaoqiang ◽  
Hua Yunpeng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatic Resection ◽  
Survival Benefit ◽  
Intermediate Stage

Potential role of cholinesterases to predict short-term outcome after hepatic resection for hepatocellular carcinoma

2012 ◽  
Vol 65 (1) ◽  
pp. 11-18 ◽  
Author(s):  
Matteo Donadon ◽  
Matteo Cimino ◽  
Fabio Procopio ◽  
Emanuela Morenghi ◽  
Marco Montorsi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatic Resection ◽  
Potential Role ◽  
Short Term ◽  
Term Outcome ◽  
Short Term Outcome

Role of the Hypoxia-Related Gene, JMJD1A, in Hepatocellular Carcinoma: Clinical Impact on Recurrence after Hepatic Resection

2011 ◽  
Vol 19 (S3) ◽  
pp. 355-364 ◽  
Author(s):  
Daisaku Yamada ◽  
Shogo Kobayashi ◽  
Hirofumi Yamamoto ◽  
Yoshito Tomimaru ◽  
Takehiro Noda ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatic Resection ◽  
Clinical Impact ◽  
Related Gene
Sign in / Sign up

Export Citation Format

Share Document